Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Explore the impact of the first-line application of Durvalumab combined with Lenvatinib, with
or without chemotherapy, on the survival, disease progression, and drug safety of patients
with advanced biliary tract cancers.